1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
3Buti M, Oyagiiez I, Lozano V, et al. Cost effectiveness of first- line oral antiviral therapies for chronic hepatitis B: a systematic review[J]. Pharmacoeconomies, 2013, 31 (1): 63-75. 被引量：1
4Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2008, 28(9): 1067-1077. 被引量：1
5Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years[J]. Aliment Pharmacol Ther, 2012, 35(11): 1326- 1335. 被引量：1
6Do,an 13/3, Kara B, Giimiirdiilfi Y, et al. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B[J]. Turk J Gastroenterol, 2012, 23 (3): 247-252. 被引量：1
7Baker DE. Adefovir dipivoxil focus on its use in the treatment of chronic hepatitis B[J]. Rev Gastroenterol Disord, 2005, 5(2): 89-100. 被引量：1
8Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog rnonotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis[J]. Pharmaeotherapy, 2013, 33(2): 144-151. 被引量：1
9Sakai T, Shiraki K, Inoue H, et al. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C[J]. Int J Mol Med, 2002,10(2): 201-204. 被引量：1
10Canestrini C, Amitrano L, Ascione A, et al. Mid-term natural course in Naples of chronic HBeAg positive infection caused by the HB- virus. Prospective study, preliminary to antiviral treatment[J]. Minerva Dietol Gastroenterol, 1989, 35(2): 119-122. 被引量：1
